Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency - PubMed (original) (raw)

Clinical Trial

Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency

Jennifer Cuellar-Rodriguez et al. Blood. 2011.

Abstract

We performed nonmyeloablative HSCT in 6 patients with a newly described genetic immunodeficiency syndrome caused by mutations in GATA2-a disease characterized by nontuberculous mycobacterial infection, monocytopenia, B- and NK-cell deficiency, and the propensity to transform to myelodysplastic syndrome/acute myelogenous leukemia. Two patients received peripheral blood stem cells (PBSCs) from matched-related donors, 2 received PBSCs from matched-unrelated donors, and 2 received stem cells from umbilical cord blood (UCB) donors. Recipients of matched-related and -unrelated donors received fludarabine and 200 cGy of total body irradiation (TBI); UCB recipients received cyclophosphamide in addition to fludarabine and TBI as conditioning. All patients received tacrolimus and sirolimus posttransplantation. Five patients were alive at a median follow-up of 17.4 months (range, 10-25). All patients achieved high levels of donor engraftment in the hematopoietic compartments that were deficient pretransplantation. Adverse events consisted of delayed engraftment in the recipient of a single UCB, GVHD in 4 patients, and immune-mediated pancytopenia and nephrotic syndrome in the recipient of a double UCB transplantation. Nonmyeloablative HSCT in GATA2 deficiency results in reconstitution of the severely deficient monocyte, B-cell, and NK-cell populations and reversal of the clinical phenotype. Registered at www.clinicaltrials.gov as NCT00923364.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Absolute number of CD3+, CD19+, NK cells, and monocytes before and after HSCT.

Figure 2

Figure 2

Median percentage of donor chimerism. Donor chimerism of CD19+, CD14+, CD3−/CD56+, and CD3+ cells at designated time points after transplantation.

Similar articles

Cited by

References

    1. Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood. 2010;115(8):1519–1529. - PMC - PubMed
    1. Bigley V, Haniffa M, Doulatov S, et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J Exp Med. 2011;208(2):227–234. - PMC - PubMed
    1. Calvo KR, Vinh DC, Maric I, et al. Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica. 2011;96(8):1221–1225. - PMC - PubMed
    1. Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118(10):2653–2655. - PMC - PubMed
    1. Scott HS, Hahn CN, Carmichael CL, et al. GATA2 is a new predisposition gene for familial myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116(21):Abstract LBA–3.

Publication types

MeSH terms

Substances

LinkOut - more resources